Read by QxMD icon Read

Venlafaxine XR

S Gibiino, A Trappoli, B Balzarro, A R Atti, D De Ronchi
A 71-year-old man developed coma with severe respiratory failure, hypotension, and tachycardia induced by the intentional ingestion of quetiapine fumarate extended release (XR) 20 g. At the time, he had been treated for bipolar depression with venlafaxine 75 mg/day, lamotrigine 100 mg/day, pregabalin 75 mg/day, and quetiapine XR 400 mg/day for approximately 1 year. Comorbidities were hypertension treated with metoprolol, diabetes mellitus type 2 treated with metformin, and benign prostatic hyperplasia treated with silodosin...
December 2015: Drug Saf Case Rep
Gayatri C Patel, Megha Kasarwala
BACKGROUND: The purpose of this study was to investigate the application of a controlled porosity osmotic tablet (CPOT) utilizing solid dispersion (SD) of poorly soluble drug. The patents on Cyclobenzaprine HCl (US4968507 A) and Venlafaxine salts (EP 2085078 A1) helped in selection of drug and polymers. METHOD: The SDs having different ratio of drug to carrier (PVP K 30) were prepared by kneading method and optimized. Effect of three independent variables, total amount of osmogen (mannitol& potassium chloride), total amount of polymer (polyethylene oxide WSR 301, hydroxy propyl methyl cellulose K100 M), and polymer1: polymer 2 ratio was investigated using Box Behnken design...
October 4, 2016: Recent Patents on Drug Delivery & Formulation
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu J Koponen, Katarzyna Kolasa
OBJECTIVES: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the Finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin-norepinephrine reuptake inhibitors. METHODS: A one-year analysis was conducted using a decision tree with a Markov state transition component. The health states were remission, relapse and recovery...
September 29, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Jonathan H Hsu, Benoit H Mulsant, Eric J Lenze, Jordan F Karp, Helen Lavretsky, Steven P Roose, Charles F Reynolds, Daniel M Blumberger
OBJECTIVE: Treatment history can inform clinical decisions about subsequent treatment choices. The authors examined the impact of prior antidepressant treatment on treatment outcomes with venlafaxine only and then with augmentation with aripiprazole or placebo in depressed older adults. METHODS: The authors analyzed outcome data from a randomized, placebo-controlled clinical trial of aripiprazole augmentation in depressed older adults. The study consisted of an open-label lead-in phase with venlafaxine XR, followed by a placebo-controlled phase of aripiprazole augmentation...
October 2016: American Journal of Geriatric Psychiatry
James Lomas, Alexis Llewellyn, Marta Soares, Mark Simmonds, Kath Wright, Alison Eastwood, Stephen Palmer
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of vortioxetine (Lundbeck) to submit clinical and cost-effectiveness evidence for vortioxetine for the treatment of major depressive episodes (MDEs), as part of the Institute's Single Technology Appraisal (STA) process. The Centre for Reviews and Dissemination and Centre for Health Economics at the University of York were commissioned to act as the independent Evidence Review Group (ERG). This article provides a description of the company submission, the ERG review and the resulting NICE guidance TA367 issued in November 2015...
September 2016: PharmacoEconomics
Pilar Cristancho, Brendan O'Connor, Eric J Lenze, Daniel M Blumberger, Charles F Reynolds, David Dixon, Benoit H Mulsant
BACKGROUND: Treatment-Emergent Suicidal Ideation (TESI) in older adults is poorly understood. We characterized TESI in older depressed adults during treatment with venlafaxine and explored whether TESI is related to antidepressant exposure versus dimensions of the psychiatric illness. We examined the relationship among medication exposure, onset of TESI, and clinical characteristics. METHODS: We analyzed data on 233 clinical trial participants with major depression and no baseline suicidal ideation who were treated for up to 12 weeks with venlafaxine XR (target dose: 150-300 mg/day)...
May 9, 2016: International Journal of Geriatric Psychiatry
Catherine S Wilson, Martin Forchheimer, Allen W Heinemann, Anne Marie Warren, Cheryl McCullumsmith
OBJECTIVE: This study sought to describe the association between spiritual well-being, demographic characteristics, quality of life (QOL) and depressive symptoms following spinal cord injury (SCI). We hypothesized QOL and depressed mood would both be explained by extent of spiritual well-being, and meaning-focused (M&P) spirituality would have a stronger impact than faith-focused spirituality. METHODS: 210 individuals with SCI were screened as part of a randomized control trial of venlafaxine XR for major depressive disorder (MDD)...
April 25, 2016: Disability and Rehabilitation
Sunil Sabharwal, Dinesh Kumbhare
No abstract text is available yet for this article.
August 2016: American Journal of Physical Medicine & Rehabilitation
André Tadić, Daniel Wachtlin, Mathias Berger, Dieter F Braus, Dietrich van Calker, Norbert Dahmen, Nadine Dreimüller, Alice Engel, Stanislav Gorbulev, Isabella Helmreich, Anne-Katrin Kaiser, Kai Kronfeld, Konrad F Schlicht, Oliver Tüscher, Stefanie Wagner, Christoph Hiemke, Klaus Lieb
Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy (n = 97; venlafaxine XR for study days 15-56; in case of sustained non-improvement on day 28, lithium augmentation for days 29-56) or TAU (n = 95; escitalopram continuation; non-responders on day 28 were switched to venlafaxine XR for four weeks, i...
April 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, William Palo, Elin Reines
The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference. Symptoms following discontinuation were assessed through the Discontinuation-Emergent Signs and Symptoms checklist in three studies. Long-term (⩽52 weeks) tolerability was evaluated in five open-label extension studies...
March 2016: Journal of Psychopharmacology
Ryan T Williams, Allen W Heinemann, Holly Demark Neumann, Jesse R Fann, Martin Forchheimer, Elizabeth J Richardson, Charles H Bombardier
OBJECTIVES: To compare the measurement properties and responsiveness to change of the Patient Health Questionnaire-9 (PHQ-9), the Hopkins Symptom Checklist-20 (HSCL-20), and the Hamilton Depression Rating Scale (HAM-D) in people with spinal cord injury (SCI) diagnosed with major depressive disorder (MDD). DESIGN: Secondary analysis of depression symptoms measured at 6 occasions over 12 weeks as part of a randomized controlled trial of venlafaxine XR for MDD in persons with SCI...
June 2016: Archives of Physical Medicine and Rehabilitation
John Kasckow, Ada Youk, Stewart J Anderson, Mary Amanda Dew, Meryl A Butters, Megan M Marron, Amy E Begley, Katalin Szanto, Alexander Y Dombrovski, Benoit H Mulsant, Eric J Lenze, Charles F Reynolds
UNLABELLED: Suicide is a public health concern in older adults. Recent cross sectional studies suggest that impairments in executive functioning, memory and attention are associated with suicidal ideation in older adults. It is unknown whether these neuropsychological features predict persistent suicidal ideation. We analyzed data from 468 individuals ≥ age 60 with major depression who received venlafaxine XR monotherapy for up to 16 weeks. We used latent class growth modeling to classify groups of individuals based on trajectories of suicidal ideation...
February 2016: Journal of Psychiatric Research
Martijn Arns, Evian Gordon, Nash N Boutros
RATIONALE: Limited research is available on electrophysiological abnormalities such as epileptiform EEG or EEG slowing in depression and its association with antidepressant treatment response. OBJECTIVES: We investigated the association between EEG abnormalities and antidepressant treatment response in the international Study to Predict Optimized Treatment in Depression (iSPOT-D). METHODS: Of 1008 participants with major depressive disorder randomized to escitalopram, sertraline, or venlafaxine-XR, 622 completed 8 weeks of treatment per protocol...
December 15, 2015: Clinical EEG and Neuroscience: Official Journal of the EEG and Clinical Neuroscience Society (ENCS)
Sang-Eun Choi, Mélanie Brignone, Seong Jin Cho, Hong Jin Jeon, Rangrhee Jung, Rosanne Campbell, Clément Francois, Dominique Milea
OBJECTIVE: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. METHODS: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states...
January 13, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Mélanie Brignone, Françoise Diamand, Caroline Painchault, Shweta Takyar
OBJECTIVES: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive disorder (MDD) with inadequate response to selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy. METHODS: A systematic search was conducted for monotherapy studies in patients with MDD with inadequate response to first-line therapy. Treatments included SSRIs, SNRIs, and other antidepressants...
2016: Current Medical Research and Opinion
Stephen F Smagula, Meryl A Butters, Stewart J Anderson, Eric J Lenze, Mary Amanda Dew, Benoit H Mulsant, Francis E Lotrich, Howard Aizenstein, Charles F Reynolds
IMPORTANCE: More than 50% of older adults with late-life major depressive disorder fail to respond to initial treatment with first-line pharmacological therapy. OBJECTIVES: To assess typical patterns of response to an open-label trial of extended-release venlafaxine hydrochloride (venlafaxine XR) for late-life depression and to evaluate which clinical factors are associated with the identified longitudinal response patterns. DESIGN, SETTING, AND PARTICIPANTS: Group-based trajectory modeling was applied to data from a 12-week open-label pharmacological trial conducted in specialty care as part of the Incomplete Response in Late Life: Getting to Remission Study...
October 2015: JAMA Psychiatry
Rik van Dinteren, Martijn Arns, Leon Kenemans, Marijtje L A Jongsma, Roy P C Kessels, Paul Fitzgerald, Kamran Fallahpour, Charles Debattista, Evian Gordon, Leanne M Williams
It is essential to improve antidepressant treatment of major depressive disorder (MDD) and one way this could be achieved is by reducing the number of treatment steps by employing biomarkers that can predict treatment outcome. This study investigated differences between MDD patients and healthy controls in the P3 and N1 component from the event-related potential (ERP) generated in a standard two-tone oddball paradigm. Furthermore, the P3 and N1 are investigated as predictors for treatment outcome to three different antidepressants...
November 2015: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Charles A Hall, Kevin M Simon, Eric J Lenze, Mary Amanda Dew, Amy Begley, Meryl A Butters, Daniel M Blumberger, Jacqueline A Stack, Benoit Mulsant, Charles F Reynolds
OBJECTIVE: This study explored whether older black and white adults with major depressive disorder differed in rates of remission or attrition during open-label treatment with venlafaxine and supportive care. METHODS: A total of 47 black (10%) and 412 white (90%) adults age ≥60 were treated with open-label venlafaxine extended-release (≤300 mg per day) for 12-14 weeks during the initial phase of an multisite, randomized, placebo-controlled augmentation trial...
December 1, 2015: Psychiatric Services: a Journal of the American Psychiatric Association
Collin Zimmerman, Pamela J Atherton, Deirdre Pachman, Drew Seisler, Nina Wagner-Johnston, Shaker Dakhil, Jacqueline M Lafky, Rui Qin, Axel Grothey, Charles L Loprinzi
PURPOSE: Previous pilot data suggested that venlafaxine could prevent acute and chronic oxaliplatin-related neuropathy. The purpose of this randomized, placebo-controlled, double-blinded pilot study was to obtain additional data to support conducting a phase III trial to test the use of venlafaxine to prevent oxaliplatin neurotoxicity. METHODS: Fifty patients, scheduled to undergo oxaliplatin-based therapy (FOLFOX) for stages II-III (67%) or stage IV (33%) colon cancer, were randomized to receive venlafaxine extended release (37...
March 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Katherine A Guthrie, Andrea Z LaCroix, Kristine E Ensrud, Hadine Joffe, Katherine M Newton, Susan D Reed, Bette Caan, Janet S Carpenter, Lee S Cohen, Ellen W Freeman, Joseph C Larson, JoAnn E Manson, Kathy Rexrode, Todd C Skaar, Barbara Sternfeld, Garnet L Anderson
OBJECTIVE: To describe the effects of six interventions for menopausal vasomotor symptoms relative to control in a pooled analysis, facilitating translation of the results for clinicians and symptomatic women. The Menopause Strategies: Finding Lasting Answers for Symptoms and Health network tested these interventions in three randomized clinical trials. METHODS: An analysis of pooled individual-level data from three randomized clinical trials is presented. Participants were 899 perimenopausal and postmenopausal women with at least 14 bothersome vasomotor symptoms per week...
August 2015: Obstetrics and Gynecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"